Onconova Therapeutics, Inc. (NASDAQ:ONTX) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET

Company Participants

Bruce Mackle - LifeSci Advisors, IR

Steve Fruchtman - President and CEO

Victor Moyo - Chief Medical Officer

Mark Guerin - Chief Operating Officer and CFO

Meena Arora - VP of Global Medical Affairs & Research and Development,

Conference Call Participants

Edouard Mullarky - Guggenheim Partners

Ahu Demir - Ladenburg Thalmann

Robert LeBoyer - Noble Capital Markets

James Molloy - Alliance Global Partners

Operator

Ladies and gentlemen, thank you for standing by. Welcome to Onconova Therapeutics Third Quarter 2023 Financial Results and Business Update Conference Call. [Operator Instructions] As a reminder, this call is being recorded today, November 14, 2023.

At this time, I would like to turn the call over to Bruce Mackle of LifeSci Advisors.

Bruce Mackle

Thank you, Operator. And welcome everyone to Onconova's third quarter 2023 financial results and business update conference call. Earlier this afternoon, Onconova issued a press release reporting its financial results and business progress. If you have not yet seen this press release, it is available in the Investors and Media section of the company's website at www.onconova.com.

Following my introduction, we will hear from Onconova's President and CEO, Dr. Steve Fruchtman; Chief Medical Officer, Dr. Victor Moyo; and Chief Operating Officer and Chief Financial Officer, Mark Guerin. Onconova's VP of Global Medical Affairs & Research and Development, Meena Arora will also be available during the Q&A session following the prepared remarks.

Before we begin, I would like to remind everyone that statements made during this conference call will include forward-looking statements under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, which involves risks and uncertainties that can cause actual results to differ materially.

Forward-looking statements speak only as of the date they are made as the underlying facts and circumstances may change. Except as required by law, Onconova disclaims any obligation to update these forward-looking statements to reflect future information, events or circumstances. For more information on forward-looking statements, please review the disclaimer in today’s press release and the risk factors in the company’s SEC filings.

With that, I will now turn the call over to Onconova's President and CEO, Dr. Steve Fruchtman.

Steve Fruchtman

Thanks Bruce, and thanks to everyone who is joining us today for this call.

I'll open by saying that Onconova has made excellent progress in the third quarter of 2023. During the call today, our Chief Medical Officer, Dr. Victor Moyo; and our Chief Operating Officer and Chief Financial Officer, Mark Guerin, and I will provide you with an update on our lead program, narazaciclib. Review the data from our recent scientific presentation. Outline our upcoming milestones. Provide a brief update on the legal assertive development program. Summarize our third quarter financial results and outlook on our cash runway, and finally, and of course, importantly, open the call for your questions.